The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin

被引:113
|
作者
Dragomir, Anca [1 ]
de Wit, Meike [2 ]
Johansson, Christine [3 ]
Uhlen, Mathias [4 ]
Ponten, Fredrik [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, S-75185 Uppsala, Sweden
[2] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands
[3] AlbaNova Univ Ctr, Atlas Antibodies AB, Stockholm, Sweden
[4] KTH Royal Inst Technol, Sci Life Lab, Stockholm, Sweden
关键词
Immunohistochemistry; Cytokeratin; 20; SATB2; Colorectal cancer; Cancer of unknown primary (CUP); PROTEIN EXPRESSION; UNKNOWN PRIMARY; CYTOKERATINS; 7; CDX2; ANTIBODY; ADENOCARCINOMAS; CANCER; IMMUNOREACTIVITY; METASTASES; CARCINOMAS; LIVER;
D O I
10.1309/AJCPWW2URZ9JKQJU
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type specific antibodies, rendering an unmet need to discover, test, and validate novel markers. The SATB2 protein is selectively expressed in glandular cells from the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers. Methods: We analyzed the expression of SATB2 in all clinical cases (n = 840), in which immunohistochemistry for detection of CK20 was deemed necessary for a final diagnosis. Results: SATB2 showed a high sensitivity (93%) and specificity (77%) to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specificity increased to 100%. Conclusions: We conclude that SATB2 provides a new and advantageous supplement for clinical differential diagnostics.
引用
收藏
页码:630 / 638
页数:9
相关论文
共 50 条
  • [41] Immunohistochemical Expression of SATB2 in Malignant Melanomas
    Roge, Rasmus
    Truumees, Birgit
    Nielsen, Soren
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2024, 32 (10) : 453 - 455
  • [42] miR-3666 suppresses cellular proliferation and invasion in colorectal cancer by targeting SATB2
    Yang, Daqing
    Li, Rizeng
    Xia, Jianfu
    Li, Wencai
    Zhou, Hong
    MOLECULAR MEDICINE REPORTS, 2018, 18 (06) : 4847 - 4854
  • [43] Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall
    Neri, Giuseppe
    Arpa, Giovanni
    Guerini, Camilla
    Grillo, Federica
    Lenti, Marco Vincenzo
    Giuffrida, Paolo
    Furlan, Daniela
    Sessa, Fausto
    Quaquarini, Erica
    Viglio, Alessandra
    Ubezio, Cristina
    Pasini, Alessandra
    Ferrero, Stefano
    Sampietro, Gianluca
    Ardizzone, Sandro
    Latella, Giovanni
    Mescoli, Claudia
    Rugge, Massimo
    Zingone, Fabiana
    Barresi, Valeria
    Ciccocioppo, Rachele
    Pedrazzoli, Paolo
    Corazza, Gino Roberto
    Luinetti, Ombretta
    Solcia, Enrico
    Paulli, Marco
    Di Sabatino, Antonio
    Vanoli, Alessandro
    CANCERS, 2020, 12 (11) : 1 - 14
  • [44] Overexpression of miR-599 is associated with metastasis in colorectal cancer via inhibition of SATB2
    Gu, Jing-Feng
    Wang, Gui-Qi
    Gao, Ying-Chao
    Dai, Yong-Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (06): : 6701 - 6709
  • [45] SATB2 as a Marker of the Proximal Nephron: Expression in Nephrogenic Adenoma and Correlation With Other Renal Tubular Markers
    Ortiz-Rey, Jose-Antonio
    Alvarez-Sarria, Miguel
    Conde-Ferreiros, Marta
    Morellon-Baquera, Raquel
    Bellas-Pereira, Alejandro
    Baltazar, Sara T.
    Garcia-Acuna, Silvia
    Fraile, Pilar San-Miguel
    Suarez-Penaranda, Jose-Manuel
    Fernandez-Baltar, Carlos
    Vieytes-Molares, Montserrat
    Dominguez-Aristegui, Patricia
    Gomez-de Maria, Carolina
    Fachal-Bermudez, Carmen
    Gonzalez-Carrero, Joaquin
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2023, 31 (03) : 145 - 153
  • [46] Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers
    Lee, Ji-Ae
    Park, Hye Eun
    Jin, Hye-Yeong
    Jin, Lingyan
    Cho, Nam-Yun
    Bae, Jeong Mo
    Kim, Jung Ho
    Kang, Gyeong Hoon
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 71
  • [47] SATB2 is expressed in neuroendocrine carcinoma of the uterine cervix
    Inzani, Frediano
    Angelico, Giuseppe
    Santoro, Angela
    Travaglino, Antonio
    Insabato, Luigi
    Raffone, Antonio
    Arciuolo, Damiano
    Scaglione, Giulia
    D'Alessandris, Nicoletta
    Valente, Michele
    Carlino, Angela
    Rindi, Guido
    Zannoni, Gian Franco
    VIRCHOWS ARCHIV, 2022, 480 (04) : 873 - 877
  • [48] SATB2 is a novel biomarker and therapeutic target for cancer
    Roy, Sanjit K.
    Shrivastava, Anju
    Srivastav, Sudesh
    Shankar, Sharmila
    Srivastava, Rakesh K.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (19) : 11064 - 11069
  • [49] CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer
    Sirnio, Paeivi
    Elomaa, Hanna
    Tuomisto, Anne
    Aijala, Ville K.
    Karjalainen, Henna
    Kastinen, Meeri
    Tapiainen, Vilja V.
    Sirkia, Onni
    Ahtiainen, Maarit
    Helminen, Olli
    Wirta, Erkki-Ville
    Rintala, Jukka
    Merilainen, Sanna
    Saarnio, Juha
    Rautio, Tero
    Seppala, Toni T.
    Bohm, Jan
    Mecklin, Jukka-Pekka
    Makinen, Markus J.
    Vayrynen, Juha P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (04)
  • [50] Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma
    Ma, Changqing
    Henn, Patrick
    Miller, Caitlyn
    Herbst, Cameron
    Hartman, Douglas J.
    Pai, Reetesh K.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (10) : 1314 - 1322